Is NBIS Stock a Buy After Falling From Its All Time High? What the $37 Billion RPO Actually Implies

What the All Time High Actually Priced

Before evaluating whether NBIS is a buy after falling from its all time high, establishing what the $299.86 peak was pricing prevents the most common error in post-peak buy analysis, which is treating any price below the peak as automatically more attractive without examining whether the peak was justified.

The all-time high of $299.86 on June 22, 2026, according to TradingView, occurred shortly after Nebius earned a spot in the Nasdaq-100 Index, according to Barchart. Index inclusion is a mechanical demand catalyst that increases buying from passive funds without any corresponding change in the underlying business. A price peak produced in part by index inclusion mechanics is a price that reflects institutional buying demand rather than a pure fundamental re-rating of the business.

The all-time high also arrived before the Q2 earnings report had confirmed the revenue trajectory. According to Barchart, much of the momentum leading to the June peak took shape after Nebius delivered a strong first quarter 2026 earnings report in May. The $299.86 peak therefore priced an extrapolation of Q1's trajectory rather than Q2's confirmation of it.

That distinction matters for the buy decision. A stock whose all-time high priced a trajectory before it was confirmed by sequential financial statements is a stock where the confirmed trajectory now available from Q2 provides a more defensible basis for the current price than the extrapolation available at the peak. The question is whether the confirmed trajectory justifies the current price rather than whether it justifies the peak price.

What the 35% Decline Before Earnings Was Actually About

Understanding what produced the 35% decline from the all time high to the pre-earnings level provides the context for evaluating whether the recovery after Q2 is warranted or whether the decline's causes remain unresolved.

According to Barchart, after soaring to an all-time closing high of $299.86, the stock cooled as investors took profits and concerns emerged that valuations across the AI sector had become stretched. The two causes identified are profit-taking and sector wide valuation concern rather than anything specific to Nebius's operations.

According to CNN citing TipRanks, Michael Burry disclosed a short position in NBIS ahead of the Q2 earnings report. According to TipRanks, approximately 42% of NBIS shares were sold short ahead of Q2 earnings, making it one of the most heavily shorted stocks in the AI sector.

A stock with 42% short interest entering a major earnings report is in a structurally specific position. Short sellers who established positions at or near the all-time high were betting that the Q2 results would not justify the premium the peak had established. The Q2 beat of analyst EPS expectations by 85.37%, according to Public.com, combined with 454% revenue growth and the $37 billion RPO, directly addressed the concern that valuation was stretched relative to actual results. The post-earnings recovery is therefore partly a fundamental re-rating and partly a short squeeze as 42% short interest faces a result that undermines the short thesis.

What the $37 Billion RPO Actually Implies for the Buy Decision

The $37 billion remaining performance obligation is the single metric most directly relevant to the buy decision because it addresses the sustainability concern more specifically than any other available data point.

According to Yahoo Finance, Nebius's remaining performance obligations reached $37 billion in Q2 2026. According to Motley Fool, a significant portion of this reflects a $27 billion five-year deal with Meta Platforms based on Nebius's first large-scale deployment of Nvidia's Vera Rubin chips.

The analytical implication of the $37 billion RPO for the buy decision is that the revenue Nebius will recognize over the coming years is contracted rather than dependent on new sales. A company whose future revenue is already signed under take-or-pay contracts is not subject to the same demand cycle risk as a company whose revenue depends on winning new customers each quarter. The RPO is the financial structure that converts the buy thesis from a bet on continued AI infrastructure spending to a bet on Nebius executing against obligations that have already been legally formalized.

The specific risk the $37 billion RPO does not eliminate is execution risk. Contracted revenue requires capacity delivery on the schedule that the contracts specify. If capacity expansion is delayed, contracted revenue is delayed with it. The Davidson analyst who cut the NBIS price target before Q2 earnings, according to CNN citing TipRanks, specifically cited what was described as Vineland delays challenging the company's narrative, referencing the potential for infrastructure buildout timing to affect revenue recognition.

The Q2 result that raised the contracted power target to 5 gigawatts by year end 2026, according to Yahoo Finance, directly addresses the capacity delivery timeline by confirming that power acquisition, which is the prerequisite for data center operation, is tracking toward the contracted delivery schedule.

The Michael Burry Short That the Q2 Beat Did Not Fully Resolve

One specific analytical consideration for the buy decision is what Michael Burry's short position represents and whether the Q2 beat resolves the concerns it reflects.

According to CNN citing TipRanks, Michael Burry announced a short position in NBIS, with one report describing his commentary as noting that valuations across AI stocks had become disconnected from fundamental value. The same source noted he also shorted Oracle alongside Nebius.

Burry's short thesis, based on available public commentary, is a valuation argument rather than a business quality argument. Burry is not arguing that Nebius's revenue is fake or that its customers will cancel. He is arguing that the price the market assigns to that revenue is too high relative to the risks that remain.

The Q2 beat resolves part of the execution risk Burry's short thesis implicitly incorporated. A result that beats EPS expectations by 85.37% and delivers 454% revenue growth is a result that removes the most immediate execution concern. What it does not resolve is the valuation concern that the price-to-sales multiple substantially above the sector average embeds.

For the buy decision, Burry's short position is most useful as a reminder that the bull case requires the premium valuation to be justified by continued extraordinary execution rather than simply by the execution that Q2 confirmed. A stock that trades at a substantial premium to sector peers needs to keep delivering results that justify the premium rather than simply maintain it.

The Three Investor Profiles and Their Different Answers

Rather than a universal buy or wait recommendation, mapping which investor profiles find the current setup attractive provides more useful guidance than any directional call.

Long-term investors with an eighteen to thirty-six month horizon who believe the $37 billion RPO converts to recognized revenue on the capacity delivery timeline Nebius has guided find the current price more defensible than the all-time high for a specific reason. The Q2 confirmation of 454% revenue growth and 41% adjusted EBITDA margin provides financial statement evidence that the business model achieves the economics the long-term thesis requires. An investor buying with that confirmation available is buying a confirmed trajectory rather than an extrapolated one.

Six to twelve month investors whose horizon includes the next earnings report on November 10, 2026, according to Public.com, face a more conditional calculation. The November report will be the first opportunity to assess whether the H2 revenue acceleration implied by the full-year guidance range of $3 billion to $3.4 billion, according to Motley Fool, is materializing through the capacity expansion timeline or whether Vineland-type delays are affecting the recognition schedule. Buying before November 10 accepts the binary risk that capacity delays could compress H2 revenue recognition while the full-year guidance implies substantial H2 acceleration.

Short-term traders face the most challenging setup because 42% short interest entering a major beat, according to TipRanks, has already produced a significant post earnings recovery. A short squeeze that has already partially occurred is a different setup from one that has not yet begun. The remaining short interest provides continued squeeze potential if positive news continues arriving, but the maximum momentum of the initial squeeze has likely already materialized in the post-earnings move.

What Getting Back to the All Time High Actually Requires

Mapping what recovering to $299.86 requires is more analytically useful than projecting a specific recovery timeline.

The all-time high of $299.86 was reached before the Q2 results were available, according to TradingView. The current price following Q2 confirmation of the trajectory the peak had priced in advance sits below the peak. Reaching or exceeding the peak therefore requires the market to assign at least the same premium to confirmed results that it previously assigned to projected results, which is a reasonable expectation only if the confirmed results demonstrate continued acceleration rather than deceleration.

The full year guidance of $3 billion to $3.4 billion in revenue, according to Motley Fool, implies H2 revenue substantially above H1 levels. If H2 delivers on that guidance, the trajectory confirmation available at the November earnings report would provide a more complete basis for the all-time high valuation than was available when the peak occurred. A stock that recovers to its all-time high on the basis of confirmed results rather than projected ones is a stock whose recovery is more durable than the original peak.

What could prevent the recovery is the execution risk that Davidson specifically cited before Q2, the Vineland delay concern. If H2 capacity comes online later than the contracted delivery schedule requires, the revenue recognition timeline shifts and the full-year guidance range becomes more difficult to achieve. The November report is the specific date on which the H2 trajectory becomes observable rather than projected.

For those looking to participate in global financial markets, having access to the right trading platform matters. WEEX offers crypto and stock trading products, covering major global markets including stocks and digital assets.

Conclusion

NBIS stock below its all-time high of $299.86 after Q2 results that confirmed 454% revenue growth, 41% adjusted EBITDA margin, and $37 billion in remaining performance obligations is a more defensible entry point than the all-time high itself for a specific and important reason. The Q2 results provide the financial statement confirmation that the all-time high had priced in advance without confirmation. An investor buying today is buying a confirmed trajectory rather than an extrapolated one.

What buying today does not resolve is the valuation debate that Michael Burry's short position and the premium price-to-sales multiple represent. The $37 billion RPO converts the revenue sustainability question from a demand concern to a capacity delivery concern, which is a different and more manageable risk profile. But the capacity delivery concern that Davidson cited before Q2 remains the most specific near-term risk that the November 10 earnings report will be the first opportunity to assess with actual H2 data.

The buy decision is most straightforward for long-term investors whose thesis accommodates the capacity delivery timeline uncertainty and who find the Q2 confirmation of the business model's economics sufficient to justify the current premium. It is more conditional for investors whose horizon is short enough that the November binary matters more than the confirmed long-term trajectory.

FAQ

1. What is NBIS stock's all time high and when was it reached?
According to TradingView and Robinhood, NBIS stock reached its all-time high of $299.86 on June 22, 2026. The peak occurred shortly after Nebius earned a spot in the Nasdaq-100 Index, according to Barchart, which created mechanical buying demand from passive funds alongside the fundamental momentum from the Q1 2026 earnings beat.

2. Why did NBIS fall approximately 35% from its all-time high before Q2 earnings?
According to Barchart, the decline reflected profit-taking and concerns that AI sector valuations had become stretched. According to CNN citing TipRanks, Michael Burry announced a short position in NBIS ahead of Q2. According to TipRanks, approximately 42% of NBIS shares were sold short before Q2 earnings, indicating significant institutional skepticism about whether the valuation could be sustained through the earnings test.

3. What does the $37 billion RPO actually mean for the investment case?
According to Yahoo Finance, the $37 billion remaining performance obligation represents contracted future revenue that customers have legally committed to pay. According to Motley Fool, a significant portion reflects a $27 billion five year deal with Meta Platforms. The RPO converts the revenue sustainability question from a demand concern to a capacity delivery concern, because the revenue is already contracted and the risk is execution of the infrastructure buildout rather than winning new customers.

4. What does Michael Burry's short position mean for NBIS investors?
According to CNN citing TipRanks, Burry's short position is based on a valuation argument rather than a business quality argument, with commentary suggesting AI stock prices have become disconnected from fundamental value. The Q2 beat of 85.37% on EPS expectations, according to Public.com, addresses the execution risk component of the short thesis without resolving the valuation concern. Burry's position is most useful as a reminder that maintaining the current premium requires continued extraordinary execution rather than simply the execution Q2 confirmed.

5. What is the most important upcoming signal for the NBIS recovery thesis?
The next earnings report on November 10, 2026, according to Public.com, is the most important upcoming signal because it will provide the first H2 financial data to assess whether the capacity expansion timeline is delivering the revenue acceleration that the full-year guidance range of $3 billion to $3.4 billion, according to Motley Fool, implies. A result confirming H2 acceleration on schedule would provide the most specific available evidence that the all-time high recovery is supported by confirmed trajectory rather than projected extrapolation.